Match Document Document Title
US20080241212 Biodegradable, Polymer Coverings for Breast Implants  
A biodegradable, flexible covering for a breast implant is provided which comprises one or more biodegradable polymer layers dimensioned and shaped to cover at least a portion of the breast...
US20140065231 CONTROLLED RELEASE COMPOSITIONS FOR TREATMENT OF COGNITIVE, EMOTIONAL AND MENTAL AILMENTS AND DISORDERS  
A montelukast composition having a therapeutically effective amount of montelukast in a sustained release is disclosed. A montelukast composition having a therapeutically effective amount of...
US20130072509 PTEROSTILBENE AND STATIN COMBINATION FOR TREATMENT OF METABOLIC DISEASE, CARDIOVASCULAR DISEASE, AND INFLAMMATION  
A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a statin compound, and a pharmaceutically acceptable...
US20100144693 METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD)  
The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing,...
US20120245115 1-Methylnicotinaide Derivatives and Formulations of Treatment of Lipoprotein Abnormalities  
The present invention is directed to nicotinamide derivatives, and their use in treating lipoprotein abnormalities, alone or in combination with a statin.
US20070281025 Cholesterol-Interacting Layered Phyllosilicates and Methods of Reducing Hypercholesteremia in a Mammal  
Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing...
US20120220577 GLYCINE B ANTAGONISTS  
The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds...
US20110301163 QUINOLINE COMPOUNDS AS INHIBITORS OF ANGIOGENESIS, HUMAN METHIONINE AMINOPEPTIDASE, AND SIRT1, AND METHODS OF TREATING DISORDERS  
Described herein are methods of inhibiting methionine aminopeptidase or SirT1, inhibiting angiogenesis, and treating disorders (or symptoms thereof) associated with methionine aminopeptidase,...
US20070275996 Use of Statins For The Treatment Of Metabolic Syndrome  
The present invention relates to the use of a pharmaceutical composition consisting of a statin (especially fluvastatin or pitavastatin) or a pharmaceutically acceptable salt thereof and a...
US20110152317 PREVENNTING THE OCCURRENCE OF OBESITY  
Administration of autophagy inhibitor (e.g. 400 mg chloroquine daily) prevents occurrence of obesity and insulin resistance in human subject on prolonged high-fat diet.
US20120172292 METHOD FOR PROTECTION OF ANTIMICROBIAL AND ANTICANCER DRUGS FROM INACTIVATION BY NITRIC OXIDE  
This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO...
US20070196285 Novel combination of anticholinergics - B2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases  
The invention relates to novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their...
US20130236395 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY  
Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.
US20100119578 EXTRACELLULAR MATRIX MODULATING COATINGS FOR MEDICAL DEVICES  
A unique method and coatings are provided to promote/allow early stage tissue encapsulation/endothelization of medical devices while effectively controlling excessive tissue buildup by eluting...
US20120164233 PULSATILE RELEASE PHARMACEUTICAL FORMULATION OF DEXLANSOPRAZOLE  
The present invention relates to a pulsatile-release pharmaceutical formulation of dexlansoprazole composed of a single type of enteric coated pellets and the process for the preparation thereof.
US20150031714 METHODS AND COMPOSITIONS FOR PREVENTION OF ALLERGIC REACTION  
Embodiments of the invention include methods of preventing and/or reducing the risk or severity of an allergic reaction in an individual. In some embodiments, particular small molecules are...
US20150073016 ROR MODULATORS AND THEIR USES  
The invention relates to ROR modulators; compositions comprising an effective amount of a ROR modulator; and methods for treating or preventing diseases associated with ROR.
US20090306133 New Acetyl Coenzyme A Carboxylase (ACC) Inhibitors And Uses In Treatments Of Obesity And Diabetes Mellitus - 087  
The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R1, R2, R3,...
US20090197858 HYPERCHOLESTROLEMIA AND TENDINOUS INJURIES  
This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating...
US20130150311 MIXED POLOXAMER EXCIPIENTS  
In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and...
US20090118269 Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds  
Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.
US20100099693 NEW COMBINATION FOR USE IN THE TREATMENT OF INFLAMMATORY DISORDERS  
There is provided combination products comprising (a) ramatroban, or a pharmaceutically-acceptable salt or solvate thereof and (b) a statin, or a pharmaceutically-acceptable salt or solvate...
US20130090355 CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS  
The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated...
US20080045567 Therapeutic Agent for Hyperlipemia and Therapeutic Agent for Diabetes  
A therapeutic agent for hyperlipidemia, diabetes, or hypertriglyceridemia containing an HMG-COA reductase inhibitor and a carboxylic acid compound represented by the following formula (1) or a...
US20110256212 Use of 8-Quinolinol and its Analogs to Target Cancer Stem Cells  
8-quinolinol (8Q) and derivatives thereof for use in the treatment of proliferative diseases such as cancer, in particular slow metabolizing quiescent cancer stem cells.
US20150065538 TRPA1 ANTAGONISTS  
Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists.Compositions comprising such compounds and methods for treating conditions and disorders...
US20080319007 DEUTERIUM-ENRICHED MONTELUKAST  
The present application describes deuterium-enriched montelukast, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
US20150045300 FAST DISSOLVING PHARMACEUTICAL COMPOSITION  
The subject invention is directed to a pharmaceutical composition comprising an open matrix network carrying a pharmaceutically active ingredient, wherein the open matrix network comprises both...
US20120071503 POSITIVE ALLOSTERIC MODULATORS OF GROUP II MGLURS  
The disclosure provides compounds and compositions, and methods of using these compounds and compositions, as positive allosteric modulators of the metabotropic glutamate subtype 2 (mGlu2)...
US20120053204 Substituted quinoline-3-carboxamides as KCNQ2/3 modulators  
The invention relates to substituted quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of...
US20080293764 LPA RECEPTOR ANTAGONIST  
A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence...
US20140107074 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS  
The present disclosure is directed to compounds of the structure (X): wherein: n is 2 or 3;NHE has the structure wherein: R1 is H or —SO2—NR7R8—;R2 is selected from H, —NR7(CO)R8, —SO2—NR7R8— and...
US20090181111 Saponin And Preservative Compositions For Reduction of Protozoa  
The invention is related to methods and compositions for reducing protozoa populations in animals. In an embodiment, the invention includes a method for reducing protozoal populations including...
US20140005186 ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS  
Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators...
US20100285083 DRUG DELIVERY SYSTEM  
It is a main object of the present invention to provide a drug delivery system in which drugs can be changed or which can be recharged with drugs, which continuously delivers drugs at effective...
US20140329675 Honeybee Repellents and Uses Thereof  
The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal,...
US20140155261 Honeybee Repellents and Uses Thereof  
The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal,...
US20140219995 INHIBITORS OF BACTERIAL TYPE III SECRETION SYSTEM  
Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system...
US20100299766 MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE  
A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that...
US20080269282 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof  
This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I),...
US20110275649 Combination therapy for the prevention of statin induced diabetes  
Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are...
US20110312985 NARINGENIN COMPLEXES AND METHODS OF USE THEREOF  
The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.
US20110081426 AMINOTHIAZOLE MODULATORS OF BETA-3-ADRENORECEPTOR  
The present invention relates to new aminothiazole modulators of beta-3-adrenoreceptor activity, pharmaceutical compositions thereof, and methods of use thereof.
US20150126437 METHODS FOR ASSESSING REPELLANT QUALITY OF ORGANIC MATERIALS AND METHODS AND COMPOSITIONS FOR REPELLING ARTHROPODS  
The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure...
US20100239565 METHODS OF TREATMENT OF SKIN ULCERS  
Methods for treating and/or preventing skin ulcers are provided featuring administration of pharmaceutical compositions comprising inhibitors of activity or expression Of Lp-PLA2 protein to...
US20110312911 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE  
Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also...
US20110306624 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE  
Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also...
US20110172256 GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE  
Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also...
US20150104504 COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS  
The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present...
US20130295173 COMPOSITIONS OF STATINS AND OMEGA-3 FATTY ACIDS  
The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present...